Study #2023-0643
A first-in-human, phase 1, dose escalation study of SGR-2921 as monotherapy in subjects with relapsed/refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
MD Anderson Study Status
Enrolling
Treatment Agent
SGR-2921
Description
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes
Study phase:
Phase I
Physician name:
Courtney DiNardo
Department:
Leukemia
For general questions about clinical trials:
1-855-799-3642
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.